Home » Cortex Regains Rights to Develop Its Ampakine Compounds
Cortex Regains Rights to Develop Its Ampakine Compounds
Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE compounds for the treatment of schizophrenia and depression.
TheStreet
TheStreet
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May